Mismatch Repair Proteins Emerge as Precision Targets in Huntington's Disease Pathogenesis

For the roughly 30,000 Americans living with Huntington's disease and the hundreds of thousands at genetic risk, the absence of disease-modifying therapies remains a profound unmet need. A new mechanistic framework — one that shifts focus from the mutant huntingtin protein to the DNA repair machinery that makes the mutation progressively worse — may fundamentally reframe how therapeutic intervention is timed and targeted.

Huntington's disease is caused by an expanded CAG trinucleotide repeat in the HTT gene, but somatic instability — the tendency of that repeat to keep expanding in specific brain cells after birth — appears to drive much of the selective neurodegeneration. A comprehensive review in Trends in Neurosciences synthesizes converging evidence from post-mortem human brain tissue, cell culture systems, and mouse models to establish that mismatch repair (MMR) enzymes, particularly MSH3, MLH3, and PMS1, actively catalyze this pathological expansion rather than correcting it. Cell-type-specific CAG repeat sizing has now confirmed that medium spiny neurons — the population most devastated in HD — harbor disproportionately elevated somatic expansion, and that crossing distinct CAG length thresholds corresponds to discrete stages of cellular pathology, potentially explaining why disease onset correlates imperfectly with germline repeat length alone.

This review is significant because it shifts MMR proteins from incidental genetic modifiers, identified through genome-wide association studies of HD onset age, into actionable therapeutic targets. The broader research landscape supports this pivot: MSH3 knockdown in animal models demonstrably reduces somatic expansion and ameliorates some pathological markers. However, critical cautions apply. MMR proteins perform essential genome surveillance functions throughout the body, and suppressing them — even partially — raises legitimate concerns about mutagenesis and cancer risk, concerns the authors explicitly evaluate. The therapeutic window will require careful delineation, and no human clinical data yet exist for MMR-modulating strategies in neurodegeneration. This is a conceptually important synthesis that moves a mechanistic hypothesis closer to translational readiness, though substantial safety and delivery hurdles remain before clinical application.